Based on the results of this phase 1 study, a phase 2 RCT (CheckMate 069) comparing nivolumab (1 mg/kg) plus ipilimumab (3 mg/kg) for four doses followed by nivolumab (3 mg/kg) (niv/ipi) with placebo plus ipilimumab (3 mg/kg) for four doses followed by placebo (placebo/ipi) in treatment‐naive, BRAF wild‐type advanced melanoma was conducted.41 The gene discussed is BRAF; the disease is melanoma.